Cargando…
Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature
PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152099/ https://www.ncbi.nlm.nih.gov/pubmed/35656513 http://dx.doi.org/10.3389/fonc.2022.881047 |
_version_ | 1784717569414922240 |
---|---|
author | Luo, Meng Chen, Huihui Deng, Hao Jin, Yao Wang, Gui Zhang, Kun Ma, Hong Chen, Yiding Zhang, Suzhan Zhou, Jiaojiao |
author_facet | Luo, Meng Chen, Huihui Deng, Hao Jin, Yao Wang, Gui Zhang, Kun Ma, Hong Chen, Yiding Zhang, Suzhan Zhou, Jiaojiao |
author_sort | Luo, Meng |
collection | PubMed |
description | PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT. PATIENTS AND METHODS: From January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT(1-2)N(+) stage, receiving NAC with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was disease-free survival (DFS), and secondary endpoint was overall survival (OS). Comparison was conducted between PMRT and non-PMRT subgroups. RESULTS: Of the 215 eligible patients, 35.8% (77/215) cT(1-2)N(+) patients achieved ypT(0-2)N(0) after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT(0-2)N(+)). The 5-year DFS of ypT(0-2)N(0) non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT(0-2)N(0) PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT(0-2)N(0) non-PMRT subgroup and cT(1-2)N(0) subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT(0-2)N(+) PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS. CONCLUSION: An effective response to NAC (ypT(0-2)N(0)) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT(1-2)N(+) breast cancer patients with ypT(0-2)N(0) after NAC. |
format | Online Article Text |
id | pubmed-9152099 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-91520992022-06-01 Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature Luo, Meng Chen, Huihui Deng, Hao Jin, Yao Wang, Gui Zhang, Kun Ma, Hong Chen, Yiding Zhang, Suzhan Zhou, Jiaojiao Front Oncol Oncology PURPOSE: Postmastectomy radiotherapy (PMRT) after neoadjuvant chemotherapy (NAC) in breast cancer patients with initial clinical stage cT(1-2)N(+), especially for those who achieved ypT(1-2)N(0), is still controversial. This study was to evaluate the survival prognosis of cT(1-2)N(+) patients after NAC with or without PMRT, and to discuss the selection of patients who may omit PMRT. PATIENTS AND METHODS: From January 2005 to December 2017, 3055 female breast cancer patients underwent mastectomy in our medical center, among whom 215 patients of cT(1-2)N(+) stage, receiving NAC with or without PMRT were finally analyzed. The median follow-up duration was 72.6 months. The primary endpoint was disease-free survival (DFS), and secondary endpoint was overall survival (OS). Comparison was conducted between PMRT and non-PMRT subgroups. RESULTS: Of the 215 eligible patients, 35.8% (77/215) cT(1-2)N(+) patients achieved ypT(0-2)N(0) after NAC while 64.2% (138/215) of the patients remained nodal positive (ypT(0-2)N(+)). The 5-year DFS of ypT(0-2)N(0) non-PMRT was 79.5% (95% confidence interval [CI] 63.4-95.6%). No statistically significant difference was observed between the ypT(0-2)N(0) PMRT and non-PMRT subgroups for the 5-year DFS (78.5% vs 79.5%, p = 0.673) and OS (88.8% vs 90.8%, p = 0.721). The 5-years DFS didn’t obviously differ between the ypT(0-2)N(0) non-PMRT subgroup and cT(1-2)N(0) subgroup (79.5% vs 93.3%, p = 0.070). By using Cox regression model in multivariate analyses of prognosis in ypT(0-2)N(+) PMRT subgroup, HER2 overexpression and triple-negative breast cancer were significantly poor predictors of DFS and OS, while ypN stage was significant independent predictors of OS. CONCLUSION: An effective response to NAC (ypT(0-2)N(0)) indicates a sufficiently favorable prognosis, and PMRT might be omitted for cT(1-2)N(+) breast cancer patients with ypT(0-2)N(0) after NAC. Frontiers Media S.A. 2022-05-17 /pmc/articles/PMC9152099/ /pubmed/35656513 http://dx.doi.org/10.3389/fonc.2022.881047 Text en Copyright © 2022 Luo, Chen, Deng, Jin, Wang, Zhang, Ma, Chen, Zhang and Zhou https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Luo, Meng Chen, Huihui Deng, Hao Jin, Yao Wang, Gui Zhang, Kun Ma, Hong Chen, Yiding Zhang, Suzhan Zhou, Jiaojiao Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title | Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title_full | Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title_fullStr | Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title_full_unstemmed | Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title_short | Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT(1-2)N(+) Breast Cancer Patients: A Single Center Experience and Review of Current Literature |
title_sort | postmastectomy radiotherapy after neoadjuvant chemotherapy in ct(1-2)n(+) breast cancer patients: a single center experience and review of current literature |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9152099/ https://www.ncbi.nlm.nih.gov/pubmed/35656513 http://dx.doi.org/10.3389/fonc.2022.881047 |
work_keys_str_mv | AT luomeng postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT chenhuihui postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT denghao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT jinyao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT wanggui postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT zhangkun postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT mahong postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT chenyiding postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT zhangsuzhan postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature AT zhoujiaojiao postmastectomyradiotherapyafterneoadjuvantchemotherapyinct12nbreastcancerpatientsasinglecenterexperienceandreviewofcurrentliterature |